Does the media refer more to LMAT or NPCE?

In the previous week, LeMaitre Vascular and LeMaitre Vascular both had 3 articles in the media. NeuroPace's average media sentiment score of 0.33 beat LeMaitre Vascular's score of 0.10 indicating that NeuroPace is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LeMaitre Vascular 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral NeuroPace 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, NPCE or AXGN?

AxoGen has higher revenue and earnings than NeuroPace. AxoGen is trading at a lower price-to-earnings ratio than NeuroPace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NeuroPace $99.53M 5.35 -$21.47M -$0.65 N/A AxoGen $238.11M 9.26 -$15.70M -$0.64 N/A

Is NPCE or AXGN more profitable?

AxoGen has a net margin of -13.21% compared to NeuroPace's net margin of -21.67%. AxoGen's return on equity of -9.63% beat NeuroPace's return on equity. Company Net Margins Return on Equity Return on Assets NeuroPace -21.67% -108.20% -18.50% AxoGen -13.21% -9.63% -6.26%

Does the media favor NPCE or AXGN?

In the previous week, NeuroPace and NeuroPace both had 3 articles in the media. NeuroPace's average media sentiment score of 0.33 beat AxoGen's score of 0.26 indicating that NeuroPace is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroPace 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AxoGen 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, NPCE or NVCR?

NeuroPace has higher earnings, but lower revenue than NovoCure. NeuroPace is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NeuroPace $99.53M 5.35 -$21.47M -$0.65 N/A NovoCure $674.41M 2.89 -$136.23M -$1.53 N/A

Is NPCE or NVCR more profitable?

NeuroPace has a net margin of -21.67% compared to NovoCure's net margin of -25.66%. NovoCure's return on equity of -50.82% beat NeuroPace's return on equity. Company Net Margins Return on Equity Return on Assets NeuroPace -21.67% -108.20% -18.50% NovoCure -25.66% -50.82% -16.48%

Does the media prefer NPCE or NVCR?

In the previous week, NovoCure had 12 more articles in the media than NeuroPace. MarketBeat recorded 15 mentions for NovoCure and 3 mentions for NeuroPace. NeuroPace's average media sentiment score of 0.33 beat NovoCure's score of -0.12 indicating that NeuroPace is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroPace 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NovoCure 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

NeuroPace (NPCE) Competitors

$15.63 -0.11 (-0.70%)

Closing price 04:00 PM Eastern

Extended Trading

$15.66 +0.03 (+0.19%)

As of 04:25 PM Eastern

Compare

NPCE vs. LMAT, AXGN, ESTA, NVCR, and PLSE

Should you buy NeuroPace stock or one of its competitors? MarketBeat compares NeuroPace with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NeuroPace include LeMaitre Vascular (LMAT), AxoGen (AXGN), Establishment Labs (ESTA), NovoCure (NVCR), and Pulse Biosciences (PLSE). These companies are all part of the "medical equipment" industry.

How does NeuroPace compare to LeMaitre Vascular?

LeMaitre Vascular (NASDAQ:LMAT) and NeuroPace (NASDAQ:NPCE) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership.

84.6% of LeMaitre Vascular shares are held by institutional investors. Comparatively, 78.8% of NeuroPace shares are held by institutional investors. 7.4% of LeMaitre Vascular shares are held by insiders. Comparatively, 20.5% of NeuroPace shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, LeMaitre Vascular and LeMaitre Vascular both had 3 articles in the media. NeuroPace's average media sentiment score of 0.33 beat LeMaitre Vascular's score of 0.10 indicating that NeuroPace is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LeMaitre Vascular	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
NeuroPace	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

LeMaitre Vascular has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market. Comparatively, NeuroPace has a beta of 1.88, meaning that its share price is 88% more volatile than the broader market.

LeMaitre Vascular presently has a consensus target price of $112.60, suggesting a potential upside of 18.39%. NeuroPace has a consensus target price of $18.83, suggesting a potential upside of 20.49%. Given NeuroPace's stronger consensus rating and higher probable upside, analysts clearly believe NeuroPace is more favorable than LeMaitre Vascular.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LeMaitre Vascular	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

LeMaitre Vascular has a net margin of 24.35% compared to NeuroPace's net margin of -21.67%. LeMaitre Vascular's return on equity of 15.36% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LeMaitre Vascular	24.35%	15.36%	9.78%
NeuroPace	-21.67%	-108.20%	-18.50%

LeMaitre Vascular has higher revenue and earnings than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LeMaitre Vascular	$249.60M	8.71	$57.73M	$2.71	35.10
NeuroPace	$99.53M	5.35	-$21.47M	-$0.65	N/A

Summary

LeMaitre Vascular beats NeuroPace on 9 of the 15 factors compared between the two stocks.

How does NeuroPace compare to AxoGen?

NeuroPace (NASDAQ:NPCE) and AxoGen (NASDAQ:AXGN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

AxoGen has higher revenue and earnings than NeuroPace. AxoGen is trading at a lower price-to-earnings ratio than NeuroPace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroPace	$99.53M	5.35	-$21.47M	-$0.65	N/A
AxoGen	$238.11M	9.26	-$15.70M	-$0.64	N/A

78.8% of NeuroPace shares are owned by institutional investors. Comparatively, 80.3% of AxoGen shares are owned by institutional investors. 20.5% of NeuroPace shares are owned by insiders. Comparatively, 2.4% of AxoGen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

NeuroPace currently has a consensus price target of $18.83, indicating a potential upside of 20.49%. AxoGen has a consensus price target of $46.50, indicating a potential upside of 12.16%. Given NeuroPace's stronger consensus rating and higher possible upside, equities analysts clearly believe NeuroPace is more favorable than AxoGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
AxoGen	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

In the previous week, NeuroPace and NeuroPace both had 3 articles in the media. NeuroPace's average media sentiment score of 0.33 beat AxoGen's score of 0.26 indicating that NeuroPace is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroPace	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AxoGen	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

NeuroPace has a beta of 1.88, indicating that its share price is 88% more volatile than the broader market. Comparatively, AxoGen has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market.

AxoGen has a net margin of -13.21% compared to NeuroPace's net margin of -21.67%. AxoGen's return on equity of -9.63% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroPace	-21.67%	-108.20%	-18.50%
AxoGen	-13.21%	-9.63%	-6.26%

Summary

AxoGen beats NeuroPace on 9 of the 16 factors compared between the two stocks.

How does NeuroPace compare to Establishment Labs?

Establishment Labs (NASDAQ:ESTA) and NeuroPace (NASDAQ:NPCE) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, institutional ownership, valuation, risk, analyst recommendations and earnings.

Establishment Labs has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market. Comparatively, NeuroPace has a beta of 1.88, indicating that its stock price is 88% more volatile than the broader market.

NeuroPace has lower revenue, but higher earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than NeuroPace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Establishment Labs	$229.58M	9.59	-$51.06M	-$1.49	N/A
NeuroPace	$99.53M	5.35	-$21.47M	-$0.65	N/A

Establishment Labs has a net margin of -19.05% compared to NeuroPace's net margin of -21.67%. NeuroPace's return on equity of -108.20% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Establishment Labs	-19.05%	-218.77%	-12.31%
NeuroPace	-21.67%	-108.20%	-18.50%

72.9% of Establishment Labs shares are held by institutional investors. Comparatively, 78.8% of NeuroPace shares are held by institutional investors. 10.0% of Establishment Labs shares are held by company insiders. Comparatively, 20.5% of NeuroPace shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Establishment Labs presently has a consensus price target of $87.14, indicating a potential upside of 16.44%. NeuroPace has a consensus price target of $18.83, indicating a potential upside of 20.49%. Given NeuroPace's stronger consensus rating and higher possible upside, analysts plainly believe NeuroPace is more favorable than Establishment Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

In the previous week, NeuroPace had 3 more articles in the media than Establishment Labs. MarketBeat recorded 3 mentions for NeuroPace and 0 mentions for Establishment Labs. NeuroPace's average media sentiment score of 0.33 beat Establishment Labs' score of 0.00 indicating that NeuroPace is being referred to more favorably in the news media.

Company	Overall Sentiment
Establishment Labs	Neutral
NeuroPace	Neutral

Summary

NeuroPace beats Establishment Labs on 12 of the 17 factors compared between the two stocks.

How does NeuroPace compare to NovoCure?

NeuroPace (NASDAQ:NPCE) and NovoCure (NASDAQ:NVCR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment.

NeuroPace has a beta of 1.88, meaning that its stock price is 88% more volatile than the broader market. Comparatively, NovoCure has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market.

NeuroPace currently has a consensus target price of $18.83, suggesting a potential upside of 20.49%. NovoCure has a consensus target price of $27.29, suggesting a potential upside of 61.93%. Given NovoCure's higher possible upside, analysts plainly believe NovoCure is more favorable than NeuroPace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
NovoCure	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

78.8% of NeuroPace shares are held by institutional investors. Comparatively, 84.6% of NovoCure shares are held by institutional investors. 20.5% of NeuroPace shares are held by company insiders. Comparatively, 5.5% of NovoCure shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, NovoCure had 12 more articles in the media than NeuroPace. MarketBeat recorded 15 mentions for NovoCure and 3 mentions for NeuroPace. NeuroPace's average media sentiment score of 0.33 beat NovoCure's score of -0.12 indicating that NeuroPace is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroPace	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NovoCure	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NeuroPace has higher earnings, but lower revenue than NovoCure. NeuroPace is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroPace	$99.53M	5.35	-$21.47M	-$0.65	N/A
NovoCure	$674.41M	2.89	-$136.23M	-$1.53	N/A

NeuroPace has a net margin of -21.67% compared to NovoCure's net margin of -25.66%. NovoCure's return on equity of -50.82% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroPace	-21.67%	-108.20%	-18.50%
NovoCure	-25.66%	-50.82%	-16.48%

Summary

NeuroPace beats NovoCure on 9 of the 16 factors compared between the two stocks.

How does NeuroPace compare to Pulse Biosciences?

Pulse Biosciences (NASDAQ:PLSE) and NeuroPace (NASDAQ:NPCE) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk and earnings.

Pulse Biosciences has a beta of 1.65, meaning that its stock price is 65% more volatile than the broader market. Comparatively, NeuroPace has a beta of 1.88, meaning that its stock price is 88% more volatile than the broader market.

In the previous week, NeuroPace had 2 more articles in the media than Pulse Biosciences. MarketBeat recorded 3 mentions for NeuroPace and 1 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 1.00 beat NeuroPace's score of 0.33 indicating that Pulse Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Pulse Biosciences	Positive
NeuroPace	Neutral

NeuroPace has higher revenue and earnings than Pulse Biosciences. NeuroPace is trading at a lower price-to-earnings ratio than Pulse Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$751K	2,289.18	-$72.78M	-$1.10	N/A
NeuroPace	$99.53M	5.35	-$21.47M	-$0.65	N/A

Pulse Biosciences currently has a consensus price target of $30.67, indicating a potential upside of 23.46%. NeuroPace has a consensus price target of $18.83, indicating a potential upside of 20.49%. Given Pulse Biosciences' higher probable upside, research analysts plainly believe Pulse Biosciences is more favorable than NeuroPace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

Pulse Biosciences has a net margin of 0.00% compared to NeuroPace's net margin of -21.67%. Pulse Biosciences' return on equity of -86.67% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	N/A	-86.67%	-73.61%
NeuroPace	-21.67%	-108.20%	-18.50%

76.9% of Pulse Biosciences shares are held by institutional investors. Comparatively, 78.8% of NeuroPace shares are held by institutional investors. 74.0% of Pulse Biosciences shares are held by company insiders. Comparatively, 20.5% of NeuroPace shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

NeuroPace beats Pulse Biosciences on 10 of the 17 factors compared between the two stocks.

Get NeuroPace News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NPCE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NPCE vs. The Competition

Export

Metric	NeuroPace	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$536.64M	$7.08B	$6.43B	$12.05B
Dividend Yield	N/A	1.20%	2.67%	5.56%
P/E Ratio	-24.05	46.41	23.75	23.75
Price / Sales	5.35	43.99	480.27	84.51
Price / Cash	N/A	25.19	26.99	37.25
Price / Book	27.42	6.89	10.28	6.78
Net Income	-$21.47M	$159.22M	$3.57B	$337.51M
7 Day Performance	-5.33%	-2.29%	-1.43%	-2.72%
1 Month Performance	-14.82%	2.25%	3.27%	1.87%
1 Year Performance	18.86%	-3.09%	23.37%	26.61%

NeuroPace Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NPCE NeuroPace	3.1363 of 5 stars	$15.63 -0.7%	$18.83 +20.5%	+19.7%	$536.64M	$99.53M	N/A	170
LMAT LeMaitre Vascular	4.5971 of 5 stars	$91.18 -0.3%	$112.60 +23.5%	+12.3%	$2.16B	$249.60M	33.40	490
AXGN AxoGen	2.425 of 5 stars	$39.58 +2.2%	$46.50 +17.5%	+291.9%	$2.10B	$238.11M	N/A	450	Positive News Analyst Downgrade
ESTA Establishment Labs	2.3972 of 5 stars	$71.32 +4.8%	$87.14 +22.2%	+95.6%	$2.00B	$229.58M	N/A	1,004	Positive News Analyst Forecast Gap Up
NVCR NovoCure	2.5581 of 5 stars	$15.80 -4.6%	$27.29 +72.7%	+0.9%	$1.97B	$674.41M	N/A	1,605	News Coverage Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NPCE) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NeuroPace (NPCE) Competitors

NPCE vs. LMAT, AXGN, ESTA, NVCR, and PLSE

How does NeuroPace compare to LeMaitre Vascular?

Summary

How does NeuroPace compare to AxoGen?

Summary

How does NeuroPace compare to Establishment Labs?

Summary

How does NeuroPace compare to NovoCure?

Summary

How does NeuroPace compare to Pulse Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NPCE vs. The Competition

NeuroPace Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NeuroPace (NPCE) Competitors

NPCE vs. LMAT, AXGN, ESTA, NVCR, and PLSE

How does NeuroPace compare to LeMaitre Vascular?

Do institutionals and insiders hold more shares of LMAT or NPCE?

Does the media refer more to LMAT or NPCE?

Which has more risk & volatility, LMAT or NPCE?

Do analysts rate LMAT or NPCE?

Is LMAT or NPCE more profitable?

Which has stronger valuation & earnings, LMAT or NPCE?

Summary

How does NeuroPace compare to AxoGen?

Which has stronger valuation & earnings, NPCE or AXGN?

Do insiders and institutionals believe in NPCE or AXGN?

Do analysts prefer NPCE or AXGN?

Does the media favor NPCE or AXGN?

Which has more volatility and risk, NPCE or AXGN?

Is NPCE or AXGN more profitable?

Summary

How does NeuroPace compare to Establishment Labs?

Which has more risk & volatility, ESTA or NPCE?

Which has preferable earnings and valuation, ESTA or NPCE?

Is ESTA or NPCE more profitable?

Do institutionals and insiders believe in ESTA or NPCE?

Do analysts recommend ESTA or NPCE?

Does the media refer more to ESTA or NPCE?

Summary

How does NeuroPace compare to NovoCure?

Which has more risk & volatility, NPCE or NVCR?

Do analysts rate NPCE or NVCR?

Do institutionals & insiders hold more shares of NPCE or NVCR?

Does the media prefer NPCE or NVCR?

Which has higher earnings & valuation, NPCE or NVCR?

Is NPCE or NVCR more profitable?

Summary

How does NeuroPace compare to Pulse Biosciences?

Which has more volatility and risk, PLSE or NPCE?

Does the media favor PLSE or NPCE?

Which has stronger valuation and earnings, PLSE or NPCE?

Do analysts recommend PLSE or NPCE?

Is PLSE or NPCE more profitable?

Do insiders & institutionals believe in PLSE or NPCE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NPCE vs. The Competition

NeuroPace Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools